References
Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101(3):513–23.
Chang TS, Wu YC, Tung SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110(6):836–44. quiz 845.
Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(1):157–64.
Kudo A, Matsumura S, Ban D, et al. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res. 2014;44(14):E437–46.
Abdel-Hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumour Biol. 2015: [Epub ahead of print].
Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.
Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol. 2014;35(9):8355–8.
Zhong JH, You XM, Lu SD, et al. Historical comparison of overall survival after hepatic resection for patients with large and/or multinodular hepatocellular carcinoma. Med (Baltimore). 2015;94(35), e1426.
Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–5.
Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.
Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339–64.
Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44(10):E11–25.
Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. PLoS One. 2015;10(10):e0140067.
Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12:17.
Jia Z, Wang L, Liu C, Yu Z, Chai L, Zhao M. Evaluation of alpha-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014;18(3):192–6.
Zhao Y, Wang M, Cui C, et al. Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. Cancer Biomark. 2015;15(5):677–83.
Acknowledgement
This study was supported by projects from the Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province (nos. Z2015716, Z2015601, Z2015621, Z2014241).
Conflicts of interests
The authors declare that they have no conflicts of interest concerning this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Liu-Cheng Wu and Wen-Feng Gong contributed equally to this work.
Rights and permissions
About this article
Cite this article
Wu, LC., Gong, WF. & Zhong, JH. A premature proposal for new liver cancer seromarkers. Tumor Biol. 37, 4293–4294 (2016). https://doi.org/10.1007/s13277-016-4801-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-4801-z